The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical Trial

Abstract

No AccessJournal of UrologyAdult urology1 May 2006The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical Trial Rauf Taner Di̇vri̇k, Ümi̇t Yildirim, Ferruh Zorlu, and Haluk Özen Rauf Taner Di̇vri̇kRauf Taner Di̇vri̇k Department of Urology, SB Tepecik Research and Teaching Hospital, İzmir , Ümi̇t YildirimÜmi̇t Yildirim Department of Urology, SB Tepecik Research and Teaching Hospital, İzmir , Ferruh ZorluFerruh Zorlu Department of Urology, SB Tepecik Research and Teaching Hospital, İzmir , and Haluk ÖzenHaluk Özen Department of Urology, Hacettepe University, Ankara, Turkey View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)01002-5AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compared the outcomes of repeat transurethral resection plus intravesical mitomycin C with initial transurethral resection of bladder plus intravesical MMC in patients with newly diagnosed pT1 transitional cell carcinoma of the bladder in terms of recurrence, progression and overall survival. Materials and Methods: Of 148 newly diagnosed patients with T1 bladder cancer 142 were prospectively randomized in 2 groups between January 2001 and January 2005. A total of 74 patients underwent second TURB and received adjuvant MMC intravesically (group 1) and 68 patients received adjuvant MMC following the initial TURB (group 2). All repeat TURB operations were performed 2 to 6 weeks following initial TURB. Patients with incomplete resection, Cis or muscle invasive disease were excluded from study. The first dose of mitomycin C (40 mg per week for a total of 8 weeks) was instilled intravesically in all patients during the first 24 hours after the last surgery. Results: Mean followup was 31.5 months (range 6 to 48) with no difference between the 2 groups. The rate of recurrence-free survival was 86.35% (SE 0.4%), 77.67% and 68.72% in group 1, and 47.08%, 42.31% and 37.01% in group 2 for the first, second and third year, respectively (overall 74.32% vs 36.76%, log rank 0.0001). Recurrence was observed in 19 of the 74 (25.68%) patients in group 1 and in 43 of the 68 (63.24%) patients in group 2. Ten of the 19 (52.63%) patients in group 1 and 35 of the 43 (81.39%) patients in group 2 had recurrence within 12 months. Recurrence was observed in 17.6%, 25% and 60% of patients with G1, G2 and G3 tumors, respectively, in group 1. The same rates for group 2 were 25%, 64% and 90%. The RFS rate was significantly worse in the high grade group (G2 and G3) (p <0.001). Progression was observed at 4.05% for group 1 compared to 11.76% for group 2 (log rank 0.0974). OS was 91.89% and 89.71% in group 1 and 2, respectively (log rank 0.732). Conclusions: The high recurrence rate in patients who did not undergo ReTUR is due to a high residual tumor rate following initial TURB. The benefit of ReTUR is especially true for high grade tumors. Since intravesical MMC was present in both groups, this study has shown that intravesical chemotherapy does not compensate for inadequate resection. Progression does not seem to be affected by ReTUR although there was a trend favoring the ReTUR group. We recommend ReTUR for patients with primary high grade T1 disease to achieve better recurrence-free survival. References 1 : Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?. J Urol2006; 175: 000. Google Scholar 2 : Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol1991; 146: 316. Abstract, Google Scholar 3 : 2nd TUR for superficial bladder cancer: a must?. J Urol1998; 159: 143. abtract 542. Google Scholar 4 : The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol1999; 162: 74. Link, Google Scholar 5 : Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?. Urology2002; 59: 220. Google Scholar 6 : Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology2002; 60: 822. Google Scholar 7 : Effect of routine repeat transurethral resection for superficial bladder cancer a long-term observational study. J Urol2003; 170: 433. Link, Google Scholar 8 : Urinary bladder. In: TNM Classification of Malignant Tumours. New York: Wiley-Liss1997: 187. Google Scholar 9 : Guidelines on bladder cancer. Eur Urol2002; 41: 105. Crossref, Medline, Google Scholar 10 : Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol2003; 169: 90. Link, Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited byYanagisawa T, Miki J, Yorozu T, Iwatani K, Obayashi K, Sato S, Kimura T, Takahashi H and Egawa S (2021) Vertical Lamina Propria Invasion Diagnosed by En Bloc Transurethral Resection is a Significant Predictor of Progression for pT1 Bladder CancerJournal of Urology, VOL. 205, NO. 6, (1622-1628), Online publication date: 1-Jun-2021.Di̇vri̇k R, Şahi̇n A, Altok M, Ünlü N and Zorlu F (2007) The Frequency of Hydronephrosis at Initial Diagnosis and its Effect on Recurrence and Progression in Patients With Superficial Bladder CancerJournal of Urology, VOL. 178, NO. 3, (802-806), Online publication date: 1-Sep-2007. Volume 175Issue 5May 2006Page: 1641-1644 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsbladder neoplasmsreoperationdisease-free survivalMetricsAuthor Information Rauf Taner Di̇vri̇k Department of Urology, SB Tepecik Research and Teaching Hospital, İzmir More articles by this author Ümi̇t Yildirim Department of Urology, SB Tepecik Research and Teaching Hospital, İzmir More articles by this author Ferruh Zorlu Department of Urology, SB Tepecik Research and Teaching Hospital, İzmir More articles by this author Haluk Özen Department of Urology, Hacettepe University, Ankara, Turkey More articles by this author Expand All Advertisement PDF downloadLoading ...